Qiagen (NYSE:QGEN) Releases Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its third quarter 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.650-0.650 for the period, compared to the consensus earnings per share estimate of 0.620. The company issued revenue guidance of $548.0 million, compared to the consensus revenue estimate of $534.1 million.

Qiagen Stock Up 0.4%

Shares of QGEN traded up $0.20 during trading hours on Friday, hitting $50.42. The stock had a trading volume of 7,144,398 shares, compared to its average volume of 5,121,620. The firm has a market capitalization of $10.39 billion, a P/E ratio of 25.83, a price-to-earnings-growth ratio of 4.99 and a beta of 0.61. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The firm has a 50 day simple moving average of $44.44 and a 200-day simple moving average of $40.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The company had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. During the same period last year, the business earned $0.60 EPS. Qiagen’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts predict that Qiagen will post 2.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

QGEN has been the topic of a number of analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $52.00 price objective (down from $55.00) on shares of Qiagen in a report on Thursday. Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a research report on Friday, August 7th. DZ Bank downgraded shares of Qiagen from a “strong-buy” rating to a “hold” rating in a report on Thursday. Morgan Stanley reiterated an “overweight” rating on shares of Qiagen in a research report on Friday, September 11th. Finally, Robert W. Baird lifted their price target on Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $44.43.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen updated third-quarter 2026 guidance to adjusted EPS of $0.65 and revenue of $548 million, above consensus estimates of $0.62 and $534.1 million, respectively. The figures are consistent with the company’s preliminary results and signal better-than-expected operating performance.
• Positive Sentiment: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share. The takeover provides a defined valuation and has been unanimously accepted, with the transaction nearing completion. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Robert W. Baird raised its price target to $52 from $50 and upgraded the stock to “outperform,” citing potential value near the takeover consideration. Robert W. Baird Qiagen rating
• Neutral Sentiment: Unusually heavy call-option activity suggests increased short-term trading interest, with call purchases roughly doubling typical volume, but it does not establish a fundamental change in valuation.
• Neutral Sentiment: JPMorgan reaffirmed its “neutral” rating while lowering its price target to $52 from $55, leaving limited projected upside relative to the current trading level. JPMorgan Qiagen rating
• Negative Sentiment: Law firms Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen obtained a fair price for shareholders. Such reviews could create deal uncertainty, although they do not currently indicate that the transaction will be blocked. Brodsky & Smith shareholder investigation

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.